Glucose B. Braun

Glucose B. Braun is an intravenous solution containing glucose monohydrate as the active ingredient. The product is supplied as a sterile solution for injection, with strength not specified in the public data, and is marketed in the European Union. It is classified as a carbohydrate excipient/solvent and is used under prescription for fluid and electrolyte therapy, providing a rapid source of energy when administered intravenously.

Glucose B. Braun is indicated for several clinical situations where rapid carbohydrate supplementation or fluid replacement is required, particularly in hospital settings for patients who cannot receive nutrition orally.

- Acute treatment of hypoglycemia in patients unable to take oral glucose, providing a quick rise in plasma glucose concentration. - Intravenous fluid and electrolyte replacement for dehydrated individuals, helping to restore circulatory volume and maintain electrolyte balance. - Component of total parenteral nutrition (TPN) formulations, delivering an essential carbohydrate source for patients receiving exclusive intravenous feeding. - Peri‑operative support to maintain adequate blood glucose levels during surgery or anesthesia, reducing the risk of intra‑operative hypoglycemia. - Adjunctive therapy in critical care to meet increased metabolic demands of severely ill patients, especially those with sepsis or trauma.

Glucose B. Braun is usually well tolerated intravenously, though adverse reactions may appear. Effects are grouped as common or serious.

Common: - Mild hyperglycemia (elevated blood glucose) that typically resolves with continued monitoring and adjustment of infusion rate. - Local irritation or pain at the injection site, often transient and not requiring intervention. - Transient electrolyte disturbances, such as mild hyponatremia, that are usually corrected by routine laboratory monitoring. - Nausea or vomiting that may occur with rapid infusion and can be reduced by slowing the administration rate.

Serious: - Severe hyperglycemia that can lead to osmotic diuresis, dehydration, and the need for insulin therapy. - Allergic reactions ranging from skin rash and urticaria to anaphylaxis, requiring immediate medical attention. - Fluid overload resulting in pulmonary edema, especially in patients with compromised cardiac function. - Metabolic acidosis in individuals with impaired glucose utilization or underlying metabolic disorders.

When using Glucose B. Braun, clinicians should consider several precautions to ensure patient safety and optimal therapeutic outcomes.

- Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Assess fluid status and cardiac function to prevent fluid overload, especially in patients with heart failure. - Adjust infusion rate in patients with renal impairment to reduce the risk of electrolyte imbalance. - Use caution in individuals with known hypersensitivity to glucose solutions or related excipients. - Monitor electrolytes, particularly sodium and potassium, during prolonged therapy.

Glucose B. Braun may interact with other intravenous agents or systemic medications; awareness of potential interactions helps prevent complications.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions that may cause rapid shifts in plasma osmolality. - Mixing with calcium‑containing solutions can lead to precipitation and should be avoided.

Use with caution: - Concurrent use of diuretics, which can amplify fluid and electrolyte changes. - Administration with catecholamines (e.g., epinephrine) that may increase glucose utilization and affect blood sugar control. - Overlapping therapy with other carbohydrate‑containing solutions, requiring careful calculation of total glucose load.